Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management

By afschroeder • July 24, 2025

Lisberg A, Huppert LA, Halmos B, Ledezma B, Soto-Romano V, Traina TA. Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management. Oncologist. 2025 Jul 23:oyaf225. doi: 10.1093/oncolo/oyaf225. Epub ahead of print. PMID: 40700616.

Tags: breast neoplasm, clinical practice patterns, Datopotamab deruxtecan, drug-related side effects and adverse reactions, Hematology/Oncology, lung neoplasm, Publications

Impact of postoperative FDG-PET/CT on adjuvant head and neck cancer treatment

Courtney PT, Juarez Casillas JE, Liu EY, Sim MS, Chau LW, Lopez-Chicas RE, St John MA, Abemayor E, Blackwell KE, Chhetri DK, Gopen QS, Kedeshian[...]

Imaging Interoperability: #DitchtheDisk is a Health Equity Imperative for Lung Cancer Screening & Beyond

Tupper HI, Mendelson DS, Doo FX, Carlos RC, Bialecki B, Prosper AE, Moghanaki D, Servais EL, Flores EJ, Cummings AL. Imaging Interoperability: #DitchtheDisk is a[...]

Circulating tumor DNA detection of local recurrence in a patient with early stage triple-negative breast cancer

Alkassis S, Suresh Y, Lipsyc-Sharf M, Zhang S, Gianni C, Medford A, Bardia A, Ashouri S, Kapoor N. Circulating tumor DNA detection of local recurrence[...]